A vaccine has been developed that could spare medicine one of its hardest problems — the need to keep the product refrigerated at all times. At temperatures up to 37°C, it retains its properties and provides protection against tetanus and diphtheria.
Why does this matter? Most vaccines must be stored and transported within a “cold chain.” In hot countries, remote areas, and places with unstable infrastructure, maintaining the required temperature is especially difficult. As a result, some products lose their usability before they even reach the patient.
The new development is based on StablevaX technology, which protects the active ingredient from temperature exposure. Researchers are now checking whether the vaccine can remain effective without refrigeration for four years.
If the result is confirmed, the technology could be adapted for other vaccines and medicines. They would be easier to store and deliver to places where constant cooling is unavailable or too expensive. That would mean vaccination could become much more geographically accessible.
